Thu, Jul 24, 2014, 7:47 AM EDT - U.S. Markets open in 1 hr 43 mins

Recent

% | $
Click the to save as a favorite.

Celsion Corp. Message Board

flogonuzim 169 posts  |  Last Activity: 18 hours ago Member since: Jan 21, 2010
  • Time for volume and price to pick up through the close.

    flog

    Sentiment: Strong Buy

  • sniff......sniff.......better than freshed baked cookies. lol

    bloodfloghound

    Sentiment: Strong Buy

  • peddle to the metal........get'r done.

    Sentiment: Strong Buy

  • flogonuzim flogonuzim Jul 22, 2014 7:49 PM Flag

    yes.....it should.

    Sentiment: Strong Buy

  • Looking forward to the call.

    flog

    Sentiment: Strong Buy

  • First, who in their right mind would sell at this price? Second, who wouldn't take advantage of buying at this price?

    This is a buyers dream right now.

    flog

    Sentiment: Strong Buy

  • Celldex Therapeutics Inc (NASDAQ: CLDX ) stock is down about 47% so far year-to-date. This decline was jump-started after the company's decision to close its early stage study on CDX-1135 back in March, a potential competitor to Alexion Pharmaceuticals (NASDAQ: ALXN ) . While this was a big blow, was it really worth what Celldex has lost?

    What's the story on CDX-1135?
    In early 2014, Celldex announced that it was stopping the investigation of a small pilot study on CDX-1135 in treating dense deposit disease, or DDD. The company had aimed to test 15 patients, but had only enrolled one in a disease that effects just 300 to 500 people in the U.S.

    Treating DDD was unlikely to be a huge fundamental catalyst, but the drug's structure was exciting to investors. CDX-1135 was a complement modulator that worked by binding to certain components linked to rare diseases. Alexion Pharmaceuticals's Soliris is the same kind of drug, binding to C5; the only difference is that CDX-1135 also binds to C3.

    With Soliris being the priciest drug in the U.S., having multiple uses, and being expected to generate sales over $2 billion this year, investors were excited about CDX-1135's developmental possibilities. Theoretically, if CDX-1135 was successful, many believed it could one day challenge Alexion in treating many of the same diseases. This would consequently potentially effect Soliris' pricing and Alexion's $30 billion market capitalization. It was a big blow for Celldex to close the program, but it was possibly a big win for Alexion.

    A deep value-driving pipeline
    The fortunate fact surrounding Celldex is that it's not just a one-candidate company, but instead has a deep pipeline of promising drugs. In fact, CDX-1135 was deep in its pipeline, and much of the company's stock price run from $2.6 in 2012 to nearly $40 in 2013 was in connection to data from its breast cancer drug Glembatumumab vedotin and its brain cancer drug Rindopepimut.

    In a difficult-to-treat breast cancer population who have failed three prior treatments, more than 30% of patients responded to Glembatumumab vedotin. As for Rindopepimut, it's being studied in a Phase 3 trial as well. Moreover, Celldex doubled the size of the trial last year after identifying strong anti-tumor activity.

    Going deeper in the pipeline
    The company also has several promising early stage products like Varlilumab, a monoclonal antibody immunotherapy.

    Essentially, Varlilumab binds to cancer cells while activating certain cancer-killing proteins; it also prevents the growth of cancer-causing cells. While a maximum dose is yet to be found, Celldex found that eight of 15 patients saw their cancer stabilize with three seeing significant tumor shrinkage partway through an early-stage trial -- although it's important to note that this drug is very early in its development.

    Why dwell on CDX-1135?
    With all things considered, Celldex has a solid pipeline around it, meaning that the market's reaction to its stock may be overdone. Specifically, its breast cancer drug Glembatumumab is being tested against Xeloda, and if the data is good could see uptake upon approval. Seeing as how Xeloda had global sales of $1.7 billion in 2013, Glembatumumab could very well be a blockbuster product. Rindopepimut has the potential to earn $500 million or more in peak sales.

    Foolish thoughts
    Last year, Celldex was considered one of the most promising companies in immuno-oncology development. Looking at the company now, I think optimism is still warranted. Sure, it flunked on the development of CDX-1135. In retrospect, though, it was a very small indication, and even Alexion had avoided developing Soliris to treat DDD. Now, while there was more potential upside in the drug given the potential to take on Alexion in other indications, I think there's still plenty of opportunity with the stock.

    While biotech is an inherently risky space and investors should be particularly careful when looking at clinical-stage biotechs like Celldex, I still think that is more than enough upside in treating cancer, and Celldex's pipeline and late-stage candidates make it a company with many potential opportunities.

    Sentiment: Strong Buy

  • flogonuzim flogonuzim Jul 22, 2014 7:39 AM Flag

    I can't help but believe more partnerships are coming. I also can't help but believe BMY will buy us for $60 to $75 a share. CLDX is a rocket on a launching pad. Time of launch continues to grow closer. At some point, shorts will get caught will their highly flammable pants down. Poof!

    flog

    Sentiment: Strong Buy

  • get'r done.

    flog

    Sentiment: Strong Buy

  • flogonuzim flogonuzim Jul 21, 2014 10:09 AM Flag

    I don't know but it has been updated on Yahoo from what it was last week.

    Sentiment: Strong Buy

  • $31.00 low target
    $36.29 mean target

    Sentiment: Strong Buy

  • flogonuzim flogonuzim Jul 17, 2014 7:36 AM Flag

    Celldex is in better position now than they were at $38. The tide will change. This price decline is all due to market conditions and has nothing.......absolutely nothing to do with mechanics of the company or company leaders. Celldex is THE LEADER in immune therapy. This price is a gift. A big gift. When this turns around, I believe it will be with great fuel and fire. Hang on and wait for it to happen.
    flog

    Sentiment: Strong Buy

  • Synergy Pharmaceuticals Inc. (SGYP) today announced that it has successfully completed patient enrollment for its phase 2 trial of SP-333, Synergy’s next-generation uroguanylin analog, in patients with opioid-induced constipation (OIC).

    The multi-center, randomized, double-blind clinical trial is designed to compare a 4-week dose-ranging regimen of once-daily oral SP-333 (1.0 mg, 3.0 mg and 6.0 mg) against placebo in patients taking opioid analgesics for chronic, non-cancer pain for at least three months. The study will evaluate approximately 260 patients with OIC who have less than 3 spontaneous bowel movements (SBMs) per week and who experience constipation related symptoms. The primary endpoint of the study is mean change from baseline in the number of SBMs during Week 4 of the Treatment Period.

    Synergy plans to release top-line data from this trial in the fourth quarter of this year.

    Sentiment: Strong Buy

  • flogonuzim flogonuzim Jul 16, 2014 8:05 AM Flag

    They are THE leader in immune therapy. Everyone knows and understands this. This is an easy triple in the next 12 months imho.
    flog

    Sentiment: Strong Buy

  • flogonuzim flogonuzim Jul 14, 2014 9:41 PM Flag

    Listen to Harry.....he knows his stuff.

    Sentiment: Strong Buy

  • Reply to

    Motley Fools "are investors wrong...." article

    by georgekoustis Jul 10, 2014 12:52 PM
    flogonuzim flogonuzim Jul 10, 2014 12:55 PM Flag

    Motley Fool doesn't write anything without an agenda. Same as Frank.

    Sentiment: Strong Buy

  • what a relief.

    Sentiment: Strong Buy

  • Synergy Pharmaceuticals Inc. (SGYP) today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on its lead drug plecanatide for the treatment of irritable bowel syndrome with constipation (IBS-C). Agreement was reached with the FDA for the plecanatide pivotal phase 3 IBS-C clinical development program that is scheduled to begin in the fourth quarter of this year.

    “We are very pleased with the outcome of our meeting with the FDA and have a clear path forward to start the IBS-C registration program with plecanatide this year,” said Dr. Gary S. Jacob, Chairman and CEO of Synergy. “The pivotal phase 3 IBS-C trials will include both 3.0 mg and 6.0 mg plecanatide, which are consistent with the doses currently being evaluated in our phase 3 chronic idiopathic constipation (CIC) program. Plecanatide has demonstrated a clinical dose-response for efficacy with an excellent tolerability profile that is observed across trials. This is an important advantage as we look to bring two doses to market in both indications and provide physicians with options for addressing individual patient needs.”

    Synergy’s pivotal phase 3 IBS-C clinical development program will consist of two registration trials, each including 1,050 patients who will receive either placebo, 3.0 mg or 6.0 mg plecanatide. IBS-C patients successfully completing either of the 12-week placebo-controlled registration trials will be offered enrollment into a long-term safety trial in order to complement and support the ongoing long-term safety database for the CIC indication.

    Sentiment: Strong Buy

  • flogonuzim flogonuzim Jul 7, 2014 10:40 PM Flag

    Tomorrow would be a good day to announce whippersnapper!

    Sentiment: Strong Buy

  • Reply to

    Shave and a haircut ....... 2 bits

    by flogonuzim Jul 7, 2014 3:47 PM
    flogonuzim flogonuzim Jul 7, 2014 4:01 PM Flag

    grey......i'm very patient. :-D

    flog

    Sentiment: Strong Buy

CLSN
3.23+0.11(+3.43%)Jul 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Facebook, Inc.
NasdaqGSWed, Jul 23, 2014 4:00 PM EDT
Gilead Sciences Inc.
NasdaqGSWed, Jul 23, 2014 3:59 PM EDT